This study will investigate the long term effects of Aldara® and Solaraze® on Actinic keratoses (AKs) on the face or scalp. AKs are defined as keratotic macules, papules or plaques with superficial scale on a red base, occurring on areas of extensive damage through sunlight. AKs are mainly induced by non-ionised radiation, especially through chronic UV-exposition, primarily sunlight. MedDRA version: 9.1 Level: LLT Classification code 10000614 Term: Actinic keratosis
Conditions
Interventions
Trade Name: Aldara® 5% cream
Product Name: Aldara® 5% Cream
Pharmaceutical Form: Cream
INN or Proposed INN: Imiquimod
CAS Number: 99011-02-06
Current Sponsor code: IMIQ
Other descriptive name: 1-(2-me
Sponsors
MEDA Pharma GmbH & Co. KG
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: To be eligible, a patient must comply with all of the following criteria: 1. Immunocompetent patient. 2. A study treatment area (STA) must be identifiable: Minimum of 5 and maximum of 10 typical visible AKs in one contiguous area of up to 50 cm2 on the face or scalp. The eyelids, the inside of the nostrils or ears, or the lip area inside the vermilion border must not be part of this area. 3. A positive histological finding for early in situ SCC type AK I or II. This will be determined from the most suspicious lesion in the STA and there from the most pathological area biopsied during screening visit. This analysis will be done by the central histopathological laboratory. 4. Willingness to comply with the obligations of the study Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: A patient is ineligible and must not enter the study if any of the following criteria is met: Safety concerns: 1. History of allergic reaction to imiquimod, diclofenac, acetyl salicylic acid, other non steroidal anti-inflammatory drugs (NSAID), hyaluronic acid, or relevant excipients. 2. Pregnancy, breast-feeding or planned pregnancy during the study. Women of child bearing potential not using a highly effective method of birth control defined as those which result in a low failure rate (i.e. 1200 µg/day beclomethasone or equivalent within 4 weeks before start of study treatment. 11. History of any malignant tumour with high tumour burden or any systemic antitumour treatment (incl. radiotherapy). 12. History of any malignant skin tumour actively treated by chemotherapy or retinoids. 13. History of severe cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrine, metabolic, mental, neurological, or other disease within the last two years. 14. Mentally incapacitated patient. 15. Present or history of drug or alcohol abuse within the last 3 years. Administrative reasons: 16. Exposure to an investigational product within the last 3 months. 17. Lack of ability or willingness to give informed consent. 18. Age below 18 years. 19. Lack of willingness to have personal study related data collected, archived or transmitted according to protocol. 20. Anticipated non-availability for study visits/procedures. 21. Vulnerable subjects (such as persons kept in detention).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The primary objective of the study is to compare the long-term outcome of treatment with Aldara® 5% cream (IMIQ) and Solaraze® 3% gel (DIC) regarding recurrence rates.;Secondary Objective: Secondary objectives include the time to recurrence, long-term clinical outcome with respect to development of invasive SCC (squamous cell carcinoma), progression of SCC, need of rescue treatment, haematological changes, and cosmetic outcome.;Primary end point(s): The primary efficacy variable ("endpoint") is the (patient) recurrence rate with respect to the STA. A patient is classified as recurrent when cleared at Week 20 and having clinically at least one evident AK lesion in the STA later on. | — |
Countries
Austria, France, Germany
Outcome results
None listed